生物分析市场中的实验室自动化 - COVID-19 的增长、趋势、影响和预测（2022-2027 年）

在预测期内，生物分析市场的实验室自动化预计将以 6.1% 的复合年增长率增长。

生物技术公司和研究机构大量投资于研发活动，主要是为了开发可能增强其产品的新技术。这些公司正在蛋白质组学、药物测试、高通量筛选和组合化学方面进行投资，以开发环保生物技术试剂。因此，预计此类新兴市场的发展将有助于预测期内市场的增长。

主要亮点

• 多年来，实验室自动化已经改变了药物发现领域，主要是由于两个主要影响因素：减少错误和成本效益。此外，自动化通过促进化合物收集改变了传统的药物发现过程，使生物技术革命和众多组合技术能够识别许多目标。
• 市场生态系统中的供应商专注于有机和无机增长战略，以保持市场竞争力。例如，Agilent Technologies开发了 Seahorse XF HS 迷你分析仪，这是 Seahorse XF 平台的最新版本，可提供最佳的 Seahorse XF 数据质量、工作流程和用户体验。细胞代谢是影响细胞命运、功能和强度的主要因素。
• 此外，根据 ClinicalTrials.gov 的数据，截至 2022 年 3 月，共有 409,300 项临床试验註册。随着对研究和开发的日益关注，预计将越来越需要加强世界各地研究实验室的能力。
• COVID-19 的爆发提高了对病毒检测、跟踪和追踪的要求，而诊断实验室需要具备每天检测多达数千个样本的能力，这推动了所研究市场的增长。由于实验室自动化程度的提高，预计生物分析市场将显着增加。

主要市场趋势

血液分析仪领域的显着增长

• 自动化分析仪可以高效、快速地测量多种生物样品中的各种化学物质和其他特性，而无需人工协助。使用自动分析仪比手动分析化学反应更方便。使用控制系统和各种程序来分析化学反应。此外，自动化技术可以节省时间。
• 血液分析仪包含多个分析模块，具有自己的样品製备过程。它用于诊断许多疾病，包括感染、贫血、病毒、糖尿病、遗传问题和癌症。此外，可以调整治疗药物和非法药物的血浆药物浓度。
• 许多市场供应商都在战略性地投资于研发，以将新产品推向市场。例如，2022年3月，迈瑞推出了BC-700系列血液分析仪，结合了红细胞沉降率（ESR）检测和全血细胞计数（CBC）。此外，该系列还包括 BC-760/BC-780 两种自动上样器型号和 BC-700/BC-720 两种开瓶型号。
• 同样，2022 年 4 月，Sysmex Europe 推出了流式细胞仪 XF-1600，获得了 CE 标誌（表明符合欧洲 IVD 法规和 IVD 应用）。它是一款 10 色分析仪，专为高效可靠的免疫表型数据收集而设计。通过这种方式，新产品的推出旨在为供应商扩大销售机会。
• 此外，自动血细胞计数器通过对全血中的成分进行定性分析来帮助诊断疟疾。该分析基于对含有 DNA 并感染疟原虫的红细胞计数。2020 年 7 月，儘管受到 COVID-19 的影响，Sysmex 的自动血细胞计数器 XN-31 获得了国内销售批准，从而在日本实现了疟疾的体外诊断。

北美拥有最大的市场份额

• 该地区临床和临床前试验数量的增加增加了对快速样品分析的需求，使自动化成为促进市场增长的关键因素之一。例如，根据世界卫生组织（WHO）的数据，美国在 1999 年至 2021 年间註册的临床试验总数最高（157,618），其次是中国和日本。
• 美国政府和 FDA 的严格监管，诊断市场需求的增加，以及由于该地区心血管和神经系统疾病等各种疾病的增加而增加的发现和实验室的利用率，推动了市场的增长。我在这里.美国主导着北美市场，是该地区的主要收入来源。
• 多年来，美国一直是临床研究的先驱。该国是Pfizer, Novartis, GlaxoSmithKline, J&J, 和Novartis等主要製药公司的所在地。该国还拥有最大的合同研究组织 (CRO)。该国主要的 CRO 包括美国实验室公司控股公司、IQVIA、Syneos Health 和 Parexel International Corp.。
• 此外，许多主要供应商继续投资以扩大其在该地区的足迹，这推动了市场的增长。例如，2021 年 9 月，Thermo Fisher Scientific Inc.宣布计划投资 1.54 亿美元并创造 290 个额外工作岗位，以扩大其在北卡罗来纳州皮特县的业务。
• 该地区的产品创新也在继续增长。例如，2021 年 10 月，Sysmex America 发布了 XN-30 仅供研究使用 (RUO) 自动血液分析仪，这是第一款用于疟疾检测的自动血液分析仪。

竞争格局

生物分析中的实验室自动化市场得到巩固。主要参与者拥有最大的市场份额。此外，基于产品创新和技术进步等因素，生物分析实验室自动化市场的参与者越来越多地相互竞争。

• 2022 年 5 月 - Thermo Fisher Scientific 推出了自动 Indigo 临床化学分析仪，可在样本驱动测试中快速获得结果。它适用于小样本量并使用更少的水，使您的实验室运行更具成本效益。
• 2021 年 2 月 - Beckman Coulter 宣布推出 DxH 560 AL，这是一款台式血液分析仪，旨在缓解中小型实验室面临的时间和资源限制。自动加载、闭管抽吸和无人值守功能允许用户连续添加多达 50 个样本，提供针对血源性病原体的安全性并减少手动仪器工作。

其他福利

• Excel 格式的市场预测 (ME) 表
• 3 个月的分析师支持

目录

第 1 章 简介

• 研究假设和市场定义
• 调查范围

第二章研究方法论

第三章执行摘要

第四章市场洞察

• 市场概况
• 产业吸引力——波特五力分析
  • 供应商的议价能力
  • 买方议价能力
  • 新进入者的威胁
  • 替代品的威胁
  • 竞争对手之间的竞争
• 行业价值链分析
• 评估 COVID-19 对行业的影响

第五章市场动态

• 市场驱动力
  • 对个性化医疗的需求不断增长
  • 通过技术创新改进解决方案
• 市场製约因素
  • 设置资金要求高
• 市场技术快照（人工智能等尖端技术的影响）

第六章市场细分

• 通过提供
  • 设备
    • 自动液体处理器
    • 自动盘子处理器
    • 机械臂
    • AS/RS
    • 视觉系统
  • 软件
• 按分析仪类型
  • 生化分析仪
  • 免疫系统分析仪
  • 血液分析仪
  • 细胞计数器
  • 凝血测量仪
• 按地区列出
  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第 7 章 竞争格局

• 公司简介
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies
  • Hamilton Company
  • Siemens Healthineers AG
  • Becton Dickinson & Co.
  • Hudson Robotics Inc.
  • Beckman Coulter Inc.（Danaher Corporation）
  • Tecan Genomics Inc.
  • Shimadzu Corporation

第八章投资分析

第九章 市场潜力

Lab automation in bioanalysis market is expected to grow at a CAGR of 6.1% over the forecast period. Biotechnology companies and research organizations have been investing massive amounts in R&D activities, primarily to develop new technologies that are expected to enhance their products. These companies are investing in proteomics, drug testing, high-throughput screening, and combinational chemistry to develop an environment-friendly biotechnology reagent. Hence, such developments are expected to contribute to the growth of the market over the forecast period.

Key Highlights

• Laboratory automation transformed the realm of drug discovery over the years, primarily through two major influential factors, such as error reduction and cost-benefit. Additionally, automation transformed the traditional drug discovery process by making it feasible to identify many targets through the biotechnology revolution and numerous combinatorial technologies, which fueled compound collection.
• Vendors present in the market ecosystem focus on organic & inorganic growth strategies to stay competitive in the market. For example, Agilent Technologies has developed Seahorse XF HS Mini Analyzer, the newest addition to the Seahorse XF platform that delivers the best in Seahorse XF data quality, workflow, and user experience. Cell metabolism is a major driver of cell fate, function, and fitness.
• Moreover, according to ClinalTrials.gov, the total number of registered clinical studies as of March 2022 was 409,300. Such increased focus on research and development is expected to drive the need for enhancing laboratory capabilities across the world.
• With the outbreak of COVID-19, the lab automation in bioanalysis market will witness a significant increase in demand due to the increasing requirement for testing, tracing, and tracking of the virus and the fact that the diagnostic lab needs many capabilities to test up to thousands of samples per day is driving the lab automation in the market studied.

Key Market Trends

Hematology Analyzers Segment to Grow at a Significant Rate

• An automated analyzer, with minimal human assistance, measures various chemicals and other characteristics in several biological samples, both efficiently and quickly. The use of automated analyzers is more convenient, as compared to the manual analysis of chemical reactions. It uses control systems and different programs to analyze chemical reactions. Furthermore, it saves time due to the automation technique.
• Hematology analyzers include multiple analytical modules with unique sample preparation processes. They are used in the diagnosis of various diseases, such as infections, anemia, viruses, diabetes, genetic problems, and cancer. Moreover, they regulate the plasma drug level for both therapeutic and illicit drugs.
• Many of the market vendors are strategically investing in research and development and are introducing new products in the market. For instance, in March 2022, Mindray launched BC-700 Series, a hematology analyzer series that incorporates both the erythrocyte sedimentation rate (ESR) tests and Complete Blood Count (CBC). In addition, the series includes two autoloader models, such as the BC-760/BC-780, and two open vial models, such as the BC-700/BC-720, that are designed to empower medium-volume laboratories with advanced technologies.
• Similarly, in April 2022, Sysmex Europe launched the Flow Cytrometer XF-1600 with CE marking (indicating compliance with European IVD Regulation and IVD use). The product is a 10-color analyzer designed for highly efficient and reliable data collection in immunophenotyping. Thus, the launch of new products is driving more sales opportunities for the vendor.
• Further, the automated hematology analyzer helps diagnose malaria by conducting qualitative analyses of formed elements in whole blood. The analysis is based on counting DNA-containing, malaria-infected red blood cells that have malaria parasites. In July 2020, despite the impact of COVID-19, Sysmex received marketing approval in Japan for its Automated Hematology Analyzer XN-31, making it available for the in-vitro diagnosis of malaria in the country.

North America to Hold Largest Market Share

• A rise in the number of clinical and pre-clinical studies in the region has made the need for speedy analysis of samples imperative, making automation one of the key components contributing to the growth of the market. For instance, as per the World Health Organization, the United States had the highest total number of trials registered during 1999-2021 (157,618), followed by China and Japan.
• Strict regulations by the US government and the FDA, the growing demand in the diagnostic market, and the increasing usage of discovery and research labs, owing to the rising presence of various diseases, such as cardiovascular diseases and neurological diseases in the region, have fueled the growth of the market. The US dominates the North American market and is the major revenue contributor in the region.
• The United States has been a pioneer in clinical research for years. This country is home to some of the major pharmaceutical companies, like Pfizer, Novartis, GlaxoSmithKline, J&J, and Novartis. The country also has the highest concentration of contract research organizations (CROs). Some of the major CROs in the country are Laboratory Corp. of America Holdings, IQVIA, Syneos Health, and Parexel International Corp.
• Further, many major vendors continue to invest in expanding their footprint across the region, which is aiding the market growth. For instance, in September 2021, Thermo Fisher Scientific Inc. announced plans to invest USD 154 million and create 290 additional jobs with an expansion of its Pitt County, NC operations.
• Product innovation also continues to rise in the region. For instance, in October 2021, Sysmex America introduced the XN-30 Research Use Only (RUO) Automated Hematology Analyzer, the first automated hematology analyzer for malaria detection.

Competitive Landscape

The lab automation in bioanalysis market is consolidated. Major players have the maximum market share. Also, the players in the lab automation in bioanalysis market are increasingly competing against each other based on factors such as product innovations and technological advances.

• May 2022 - Thermo Fisher Scientific introduced the Automated Indiko Clinical Chemistry analyzer, which produces results quickly with sample-oriented testing. It can operate with low sample volumes and uses small amounts of water which enables running the laboratory more cost-efficiently.
• February 2021 - Beckman Coulter announced the launch of the DxH 560 AL, a tabletop hematology analyzer designed to reduce the time and resource constraints faced by small- to mid-sized laboratories. With its auto-loading functionality, closed tube aspiration, and walk away capabilities, users can continually add up to 50 samples, provide safety against blood-borne pathogens and spend less time on manual instrument tasks.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumption and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHTS

• 4.1 Market Overview
• 4.2 Industry Attractiveness - Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Threat of Substitutes
  • 4.2.5 Intensity of Competitive Rivalry
• 4.3 Industry Value Chain Analysis
• 4.4 Assessment of Impact of Covid-19 on the Industry

5 MARKET DYNAMICS

• 5.1 Market Drivers
  • 5.1.1 Rising Demand for Personalized Medicines
  • 5.1.2 Technological Innovations Resulting in Improved Solutions
• 5.2 Market Restraints
  • 5.2.1 High Capital Requirements for Setup
• 5.3 Technology Snapshot of the Market (Effect of AI and other Cutting-edge Technologies)

6 MARKET SEGMENTATION

• 6.1 By Offering
  • 6.1.1 Equipment
    • 6.1.1.1 Automated Liquid Handlers
    • 6.1.1.2 Automated Plate Handlers
    • 6.1.1.3 Robotic Arms
    • 6.1.1.4 AS/RS
    • 6.1.1.5 Vision Systems
  • 6.1.2 Software
• 6.2 By Type of Analyzers
  • 6.2.1 Biochemistry Analyzers
  • 6.2.2 Immuno-Based Analyzers
  • 6.2.3 Hematology Analyzers
  • 6.2.4 Cell Counters
  • 6.2.5 Coagulometers
• 6.3 By Geography
  • 6.3.1 North America
  • 6.3.2 Europe
  • 6.3.3 Asia-Pacific
  • 6.3.4 Latin America
  • 6.3.5 Middle East and Africa

7 COMPETITIVE LANDSCAPE

• 7.1 Company Profiles
  • 7.1.1 Thermo Fisher Scientific Inc.
  • 7.1.2 Agilent Technologies
  • 7.1.3 Hamilton Company
  • 7.1.4 Siemens Healthineers AG
  • 7.1.5 Becton Dickinson & Co.
  • 7.1.6 Hudson Robotics Inc.
  • 7.1.7 Beckman Coulter Inc. (Danaher Corporation)
  • 7.1.8 Tecan Genomics Inc.
  • 7.1.9 Shimadzu Corporation

8 INVESTMENT ANALYSIS

9 FUTURE OF THE MARKET